Sagimet Biosciences Inc.
No enriched coverage for $SGMT in the last 7 days.
Sagimet Biosciences (SGMT) announced its Phase 3 AURORA trial for denifanstat, a treatment for moderate to severe acne, is on track to begin enrollment in Q4 2026. The trial will involve 800 U.S. patients, with results expected to support a New Drug Application submission. Denifanstat previously succeeded in a Phase 3 trial in China. SGMT's stock closed at $10.21, down 0.38%.
Kemble George sold 350,987 shares of Sagimet Biosciences Inc. (SGMT) at $10.23 ($3.59M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
Sagimet Biosciences (Nasdaq: SGMT) said the FDA cleared its IND and issued a “Study May Proceed” letter for denifanstat, a Phase 3 FASN inhibitor for moderate to severe acne. The trial is planned to start in 2H 2026, enrolling about 800 U.S. patients (450 adolescents). Dosing is 50 mg once daily vs placebo for 12 weeks, with a 40-week open-label extension.
Recent SGMT coverage spans earnings, insider activity and corporate actions.
In the last 30 days, SGMT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($3.8M). The most active reporter was Kemble George with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The upcoming enrollment confirms trial progress but does not immediately affect near-term pricing.
This is an insider sale disclosure, not a fundamental change, but it can modestly affect near-term sentiment and positioning.
Regulatory clearance removes a key gating item for Phase 3 start, improving probability-weighted timelines and near-term development visibility.
The article ties SGMT’s move to a fresh earnings print plus a concrete Phase 3 clinical update and U.S. registrational trial timeline, supporting near-term momentum.
Wider loss plus a defined Phase 3 timeline can shift risk perception and capital runway expectations for SGMT.
alphai scores every news story that mentions SGMT with an AI model for sentiment and relevance, and aggregates insider trades from Sagimet Biosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sagimet Biosciences (SGMT) announced its Phase 3 AURORA trial for denifanstat, a treatment for moderate to severe acne, is on track to begin enrollment in Q4 2026. The trial will involve 800 U.S. patients, with results expected to support a New Drug Application submission. Denifanstat previously succeeded in a Phase 3 trial in China. SGMT's stock closed at $10.21, down 0.38%.
2 min readKemble George sold 350,987 shares of Sagimet Biosciences Inc. (SGMT) at $10.23 ($3.59M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
2 min readSagimet Biosciences (Nasdaq: SGMT) said the FDA cleared its IND and issued a “Study May Proceed” letter for denifanstat, a Phase 3 FASN inhibitor for moderate to severe acne. The trial is planned to start in 2H 2026, enrolling about 800 U.S. patients (450 adolescents). Dosing is 50 mg once daily vs placebo for 12 weeks, with a 40-week open-label extension.
4 min readSagimet Biosciences (SGMT) shares rose 3.4% pre-open to $9.84 after Q2 2026 results. The company reported a net loss of $14.0 million for the quarter ended June 30, slightly better than consensus, and reaffirmed its denifanstat pipeline. It cited Phase 3 data from Ascletis in China showing about a 20-point improvement vs placebo, with no serious adverse events, and plans a U.S. Phase 3 trial enrolling 800 patients starting H2 2026. Analysts rate it Strong Buy with a $28.50 average 12-month targe
4 min readSagimet Biosciences (SGMT) reported Q2 net loss widening to $14.0M from $10.4M a year earlier. As of June 30, 2026, it had $257.6M cash, expected to fund operations through 2028. The company plans a U.S. Phase 3 registrational trial of denifanstat for moderate-to-severe acne in H2 2026 and a Phase 2 for TVB-3567 after its Phase 1.
3 min readSagimet Biosciences (Nasdaq: SGMT) reported Q2 2026 results and updates. It plans to initiate a U.S. registrational Phase 3 for denifanstat in moderate to severe acne in 2H 2026. First-in-human Phase 1 for FASN inhibitor TVB-3567 is ongoing. In April 2026 it raised $175.0M gross. Cash and marketable securities were $257.6M at June 30, 2026, funding operations through 2028.
3 min readSagimet Biosciences Inc. (SGMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial o
4 min readHappel David (President & CEO) sold 64,051 shares of Sagimet Biosciences Inc. (SGMT) at $7.76 ($0.50M total) on 2026-07-20.
1 min readSagimet Biosciences (NASDAQ:SGMT) said it was added to the Russell 3000 and Russell 2000 indexes in the 2026 reconstitution, based on April 30 market caps. Inclusion can trigger automatic moves into Russell 1000 or 2000 and related value or growth indexes. CEO David Happel linked the visibility to its planned denifanstat Phase 3 acne study.
3 min readSagimet Biosciences Inc. (SGMT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001400118 0001400118 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read